We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile

News   Dec 14, 2007

 
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
 
 
 

RELATED ARTICLES

Compound Created to Block Therapeutic Target in Blood Cancer

News

Researchers have discovered a hyperactive cell signal that contributes to tumor growth in an aggressive blood cancer. The team has also developed an experimental therapeutic "UNC3810A" to block the signal and slow tumor growth.

READ MORE

Early Benefit Assessment Exposes Weaknesses in the Development of New Drugs

News

More than half of the drugs that have entered the market in Germany since then have emerged from these assessments without any proven added benefit. In a new publication using the first 216 assessments, researchers examine the reasons for this sobering result and develop suggestions for improvements in drug development.

READ MORE

Clinical Trial for New Anti-obesity Drug Set to Launch

News

The Alberta Diabetes Institute will be at the centre of a new clinical trial for an anti-obesity drug targeting people with rare genetic conditions that contribute to their obesity.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE